Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis

Respiratory Medicine

Volumn 105, Issue SUPPL. 2, 2011, Pages

  Geller, David E ^a   Madge, Susan ^b  

^a NEMOURS CHILDREN S HOSPITAL   (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Behavioral strategies; Cystic fibrosis; Inhaled antibiotics; Pseudomonas aeruginosa; Pulmonary exacerbations; Technological strategies; Treatment adherence

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; COLISTIMETHATE; DORNASE ALFA; FOSFOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

AEROSOL; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE THERAPY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDICAL NEBULIZER; METERED DOSE INHALER; MINIMUM INHIBITORY CONCENTRATION; MOTIVATION; MOTIVATIONAL INTERVIEWING; NEBULIZATION; PATIENT COMPLIANCE; PERSONAL CONSTRUCT PSYCHOLOGY; PRIORITY JOURNAL; PROBLEM SOLVING THERAPY; PSEUDOMONAS AERUGINOSA; PSYCHOLOGY; SPRAY DRYING; TIDAL VOLUME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; RESPIRATORY TRACT INFECTIONS;

EID: 84855266619     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/S0954-6111(11)70024-5     Document Type: Article

References (70)

1. RL Gibson, JL Burns, BW Ramsey Pathophysiology and management of pulmonary infections in cystic fibrosis Am J Respir Crit Care Med 168 2003 918 951 (Pubitemid 37267172)
2. JJ Lipuma The changing microbial epidemiology in cystic fibrosis Clin Microbiol Rev 23 2010 299 323
3. AR Hauser, M Jain, M Bar-Meir, SA McColley Clinical significance of microbial infection and adaptation in cystic fibrosis Clin Microbiol Rev 24 2011 29 70
4. PA Flume, BP O'Sullivan, KA Robinson et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health Am J Respir Crit Care Med 176 2007 957 969 (Pubitemid 350127838)
5. H Heijerman, E Westerman, S Conway, D Touw, G Doring, consensus working group Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus J Cyst Fibros 8 2009 295 315
6. SM Moskowitz, SJ Silva, N Mayer-Hamblett et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis Pediatr Pulmonol 43 2008 874 881
7. DE Geller Aerosol antibiotics in cystic fibrosis Respir Care 54 2009 658 670
8. GS Sawicki, DE Sellers, WM Robinson High treatment burden in adults with cystic fibrosis: challenges to disease self-management J Cyst Fibros 8 2009 91 96
9. MR DiMatteo Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research Med Care 42 2004 200 209
10. RP Arias Llorente, C Bousoño García, JJ Díaz Martín Treatment compliance in children and adults with cystic fibrosis J Cyst Fibros 7 2008 359 367
11. DR Czajkowski, GP Koocher Medical compliance and coping with cystic fibrosis J Child Psychol Psychiatry 28 1987 311 319
12. LJ Kettler, SM Sawyer, HR Winefield, HW Greville Determinants of adherence in adults with CF Thorax 57 2002 459 464
13. MN Eakin, A Bilderback, MP Boyle, PJ Mogayzel, KA Riekert Longitudinal association between medication adherence and lung health in people with cystic fibrosis J Cyst Fibros 10 2011 258 264
14. JL Rau Determinants of patient adherence to an aerosol regimen Respir Care 50 2005 1346 1359
15. H Milgrom, B Bender, L Ackerson, P Bowry, B Smith, C Rand Noncompliance and treatment failure in children with asthma J Allergy Clin Immunol 98 1996 1051 1057 (Pubitemid 27014796)
16. BA Briesacher, AL Quittner, L Saiman, P Sacco, H Fouayzi, LM Quittell Adherence with tobramycin inhaled solution and health care utilization BMC Pulm Med 11 2011 5
17. KC Kesser, DE Geller New aerosol delivery devices for cystic fibrosis Respir Care 54 2009 754 767
18. DE Geller The science of aerosol delivery in cystic fibrosis Pediatr Pulmonol 43 9 SupplA 2008 S5 17
19. PM Mendelman, AL Smith, J Levy, A Weber, B Ramsey, RL Davis Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum Am Rev Respir Dis 132 1985 761 765 (Pubitemid 16247735)
20. P King, O Lomovskaya, DC Griffith, JL Burns, MN Dudley In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis Antimicrob Agents Chemother 54 2010 143 148
21. BW Ramsey, HL Dorkin, JD Eisenberg et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis N Engl J Med 328 1993 1740 1746 (Pubitemid 23170123)
22. A Chuchalin, E Csiszér, K Gyurkovics et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study Paediatr Drugs 9 Suppl 1 2007 21 31 (Pubitemid 46879111)
23. AL Coates, M Green, K Leung et al. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis Pediatr Pulmonol 4 2008 753 759
24. L Dupont, P Minic, S Fustik et al. A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Cyst Fibros 7 Suppl 2 2008 S26 Abstract 102.
25. OO Okusanya, SM Bhavnani, J Hammel et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection Antimicrob Agents Chemother 53 2009 3847 3854
26. P Bruinenberg, B Otulana, J Blanchard et al. The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization Pediatr Pulmonol 43 Suppl 31 2008 344 Abstract 401.
27. EM Westerman, AH De Boer, PPH Le Brun et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study J Cyst Fibros 6 2007 284 292 (Pubitemid 46971893)
28. DE Geller, J Weers, S Heuerding Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology J Aerosol Med Pulm Drug Deliv 24 2011 175 182
29. MT Newhouse, PH Hirst, SP Duddu et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers Chest 124 2003 360 366 (Pubitemid 36851374)
30. DE Geller, M Konstan, J Smith, S Noonberg, C Conrad A novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr Pulmonol 42 2007 307 313 (Pubitemid 46608898)
31. MW Konstan, DE Geller, P Minic, F Brockhaus, J Zhang, G Angyalosi Tobramycin inhalation powder for Pseudomonas aeruginosa infection in cystic fibrosis: the EVOLVE trial Pediatr Pulmonol 46 2011 230 238
32. MW Konstan, PA Flume, M Kappler et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial J Cyst Fibros 10 2011 54 61
33. H Stass, S Baumann-Noss, H Delesen et al. Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder J Cyst Fibros 7 Suppl 2 2008 S26 Abstract 103.
34. HA Tiddens, DE Geller, P Challoner et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older J Aerosol Med 19 2006 456 465 (Pubitemid 46067764)
35. BC Trapnell, SA McColley, DG Kissner et al. Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection Am J Respir Crit Care Med 2011 (in press).
36. Y Yang, MD Tsifansky, CJ Wu, HI Yang, G Schmidt, Y Yeo Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis Pharm Res 27 2010 151 160
37. RL Gibson, GZ Retsch-Bogart, C Oermann et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis Pediatr Pulmonol 41 2006 656 665
38. DE Geller, PA Flume, D Staab, R Fischer, JS Loutit, DJ Conrad Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa Am J Respir Crit Care Med 183 2011 1510 1516
39. D Hubert, S Leroy, R Nove-Josserand et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis J Cyst Fibros 8 2009 332 337
40. W Lenney, F Edenborough, P Kho, JM Kovarik Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects J Cyst Fibros 10 2011 9 14
41. J Denyer, T Dyche The Adaptive Aerosol Delivery (AAD) technology: past, present, and future J Aerosol Med Pulm Drug Deliv 23 Suppl 1 2010 S1 10
42. P Brand, I Friemel, T Meyer, J Schulz, K Haussinger Total deposition of therapeutic particles during spontaneous and controlled inhalations J Pharm Sci 89 2000 724 731
43. P McCormack, PS McNamara, KW Southern A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis J Cyst Fibros 10 2011 343 349
44. WD Bennett Controlled inhalation of aerosolized therapeutics Expert Opin Drug Deliv 2 2005 763 767
45. J Denyer Adherence monitoring in drug delivery Expert Opin Drug Deliv 7 2010 1127 1131
46. Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis, 3rd edn. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group; 2009.
47. PS McNamara, P McCormack, AJ McDonald, L Heaf, KW Southern Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis J Cyst Fibros 8 2009 258 263
48. D Meichenbaum, DC Turk Facilitating Treatment Adherence: A Practitioner's Guidebook 1987 Plenum Press New York
49. C Gibson Perspective in parental coping with a chronically ill child: the case of cystic fibrosis Issues Compr Pediatr Nurs 11 1988 33 41
50. S Madge 'Challenges for nurses' A Bush EWFW Alton JC Davies U Griesenbach A Jaffe Cystic Fibrosis in the 21st Century. Progress in Respiratory Research vol. 34 2006 Karger Basel, Switzerland 286 292 (Pubitemid 41417566)
51. 1 in adults with CF Pediatr Pulmonol 38 2004 413 418 (Pubitemid 39425681)
52. J Moise, D Drotar, C Doershuk, RC Stern Correlates of psychosocial adjustment among young adults with cystic fibrosis J Dev Behav Pediatr 8 1987 141 148 (Pubitemid 17105962)
53. H Oxley, AK Webb How a clinical psychologist manages the problems of adults with cystic fibrosis J R Soc Med 98 Suppl 45 2005 37 46 (Pubitemid 40961812)
54. J Hafetz, VA Miller Child and parent perceptions of monitoring in chronic illness management: a qualitative study Child Care Health Dev 36 2010 655 662
55. EJ Dziuban, L Saab-Abazeed, SR Chaudhry, DS Streetman, SZ Nasr Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis Pediatr Pulmonol 45 2010 450 458
56. E Lehane, G McCarthy Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper Int J Nurs Stud 44 2007 1468 1477
57. AC Modi, AL Quittner Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 31 2006 846 858 (Pubitemid 44310212)
58. J Abbott, M Dodd, AK Webb Different perceptions of disease severity and self care between patients with cystic fibrosis, their close companions, and physician Thorax 50 1995 794 796
59. AJA Duff, GJ Latchford Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it J Cyst Fibros 9 2010 455 456
60. B Bender, H Milgrom, A Apter Adherence intervention research: what have we learned and what do we do next? J Allergy Clin Immunol 112 2003 489 494 (Pubitemid 37108550)
61. B Bender, FS Wamboldt, SL O'Connor et al. Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT Ann Allergy Asthma Immunol 85 2000 416 421
62. T Daniels, L Goodacre, C Sutton, K Pollard, S Conway, D Peckham Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers Chest 140 2011 425 432
63. RA Elliott, N Barber, R Horne Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence Ann Pharmacother 39 2005 508 515 (Pubitemid 40270917)
64. LM McClimans, M Dunn, AM Slowther Health policy, patient-centred care and clinical ethics J Eval Clin Pract 17 2011 913 919
65. AJA Duff, GJ Latchford Motivational interviewing for adherence problems in cystic fibrosis: state of the art review Pediatr Pulmonol 45 2010 211 220
66. LM Hides, KS Elkins, A Scaffidi, SM Cotton, S Carroll, DI Lubman Does the addition of integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of standard care for young people with comorbid depression and substance misuse? Med J Aust 195 2011 S31 S37
67. D Fowler, R Rollinson, P French Adherence and competence assessment in studies of CBT for psychosis: current status and future directions Epidemiol Psychiatr Sci 20 2011 121 126
68. PR Brocklehurst Personal construct psychology: a theory to help understand professional development, a philosophy to support it Prim Dent Care 17 2010 179 187
69. AM Nezu, CM Nezu, MG Perri Problem solving to promote treatment adherence WT O'Donohue ER Levensky Promoting Treatment Adherence: A Practical Handbook for Health Care Providers 2006 Sage Publications, Inc New York 135 148
70. BM Melnyk, NF Feinstein, Z Moldenhouer, L Small Coping in parents of children who are chronically ill: strategies for assessment and intervention Pediatr Nurs 27 2001 547 558